Firazyr Patient Registry Protocol (Icatibant Outcome Survey - IOS)

Trial Profile

Firazyr Patient Registry Protocol (Icatibant Outcome Survey - IOS)

Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Icatibant (Primary)
  • Indications Angioedema; Hereditary angioedema
  • Focus Adverse reactions
  • Acronyms IOS
  • Sponsors Shire
  • Most Recent Events

    • 06 Mar 2017 Results (n=229) evaluating early versus late icatibant treatment, presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 19 Dec 2016 Planned number of patients changed from 790 to 3000.
    • 19 Dec 2016 Planned End Date changed from 1 Dec 2020 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top